Searching News Database: bronchiectasis
HSMN NewsFeed - 1 Aug 2022
Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections
Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections
HSMN NewsFeed - 27 Mar 2019
Synspira Therapeutics Announces Appointment of Robert Gallotto as President and Chief Executive Officer
Synspira Therapeutics Announces Appointment of Robert Gallotto as President and Chief Executive Officer
HSMN NewsFeed - 5 Oct 2016
Insmed Announces Worldwide License Agreement with AstraZeneca for Oral DPP1 Inhibitor
Insmed Announces Worldwide License Agreement with AstraZeneca for Oral DPP1 Inhibitor
HSMN NewsFeed - 29 May 2014
Masimo Announces CE Mark of iSpO2(TM) Rx Pulse Oximeter for Mobile Devices
Masimo Announces CE Mark of iSpO2(TM) Rx Pulse Oximeter for Mobile Devices
HSMN NewsFeed - 30 Dec 2013
Electromed, Inc. Receives FDA Market Clearance for the SmartVest(R) SQL(TM)
Electromed, Inc. Receives FDA Market Clearance for the SmartVest(R) SQL(TM)
HSMN NewsFeed - 26 Oct 2012
NICE Approves Pharmaxis' Bronchitol(R) As An Important New Treatment Option For Cystic Fibrosis Patients
NICE Approves Pharmaxis' Bronchitol(R) As An Important New Treatment Option For Cystic Fibrosis Patients
HSMN NewsFeed - 11 Jan 2011
SUMAVEL DosePro Receives Marketing Approval in Germany and the United Kingdom
SUMAVEL DosePro Receives Marketing Approval in Germany and the United Kingdom
HSMN NewsFeed - 10 Aug 2007
MAP Pharmaceuticals Promotes Stephen B. Shrewsbury to Position of Chief Medical Officer
MAP Pharmaceuticals Promotes Stephen B. Shrewsbury to Position of Chief Medical Officer
HSMN NewsFeed - 5 Jul 2007
Aradigm Corporation Names Norman Halleen as Interim Chief Financial Officer
Aradigm Corporation Names Norman Halleen as Interim Chief Financial Officer
HSMN NewsFeed - 5 Jun 2007
Aradigm Names D. Jeffery Grimes as General Counsel and Corporate Secretary
Aradigm Names D. Jeffery Grimes as General Counsel and Corporate Secretary
HSMN NewsFeed - 16 Jan 2007
Aradigm Receives FDA Orphan Drug Designation for Liposomal Ciprofloxacin for Bronchiectasis
Aradigm Receives FDA Orphan Drug Designation for Liposomal Ciprofloxacin for Bronchiectasis
Additional items found! 3
Members Archive contains
3 additional stories matching:
bronchiectasis
(Password required)
bronchiectasis
(Password required)